Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$6.61 – $7.02
Volume24,166
Market cap$27M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$26.85M
Price / earnings
—
Price / book
0.81×
Price / sales
0.37×
EV / sales
0.35×
EV / EBITDA
-11.6×
Profitability
Earnings per share
-$1.46
Return on assets
-10.18%
Return on equity
-17.53%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.29×
Current ratio
2.47×
Quick ratio
2.27×
Cash ratio
0.71×
Cash flow
Price / cash flow
10.03×
Price / free cash flow
32.43×
Free cash flow
$828K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RMTI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$19.12M
$17.78M
$17.34M
$18.35M
$15.93M
$16.07M
$18.91M
$24.67M
Cost of revenue
$16.01M
$14.54M
$14.44M
$14.47M
$13.66M
$13.57M
$15.87M
$21.03M
Gross profit
$3.11M
$3.24M
$2.9M
$3.88M
$2.27M
$2.5M
$3.04M
$3.63M
Selling, general and administrative
$4.37M
$4.26M
$4.38M
$4.28M
$3.86M
$3.85M
$4.4M
$4.15M
Research and development
$114K
$40K
$0
$0
$0
$0
$0
$1K
Total operating expenses
$5.33M
$4.3M
$4.38M
$4.28M
$3.86M
$3.85M
$4.4M
$4.15M
Operating income
-$2.22M
-$1.06M
-$1.48M
-$398K
-$1.58M
-$1.35M
-$1.36M
-$519K
Interest expense
-$282K
-$281K
-$282K
-$286K
-$285K
-$276K
-$277K
-$289K
Income before taxes
-$2.32M
-$1.17M
-$1.61M
-$554K
-$1.75M
-$1.49M
-$1.52M
-$756K
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.32M
-$1.17M
-$1.61M
-$554K
-$1.75M
-$1.49M
-$1.52M
-$756K
Net income attributable to common shareholders
-$2.32M
-$1.33M
-$1.61M
-$554K
-$1.75M
-$1.65M
-$1.52M
-$756K
EBITDA
-$824K
-$569K
-$969K
$148K
-$1.04M
-$786K
-$821K
$24K
Basic earnings per share
-$0.59
-$0.34
-$0.40
-$0.14
-$0.49
-$0.48
-$0.40
-$0.23
Diluted earnings per share
-$0.59
-$0.34
-$0.40
-$0.14
-$0.49
-$0.48
-$0.40
-$0.25
Recent news
Company coverage with links to the original publishers.
Rockwell Medical reported a quarterly loss of $0.59 per share, significantly worse than the consensus estimate of $0.18, representing a -227.78% earnings surprise. The company posted revenues of $19.12 million, slightly beating estimates but has underperformed the S&P 500 by 26.4% year-to-date. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 42% of performance, the stock is expected to perform in line with the market.
Curaleaf Holdings reported a Q3 loss of $0.14 per share, beating the consensus estimate of $0.16 loss, with a 12.50% earnings surprise. Revenue reached $352.65 million, surpassing estimates by 1.79% and up from $320.24 million year-over-year. The stock has gained 21.2% year-to-date, outperforming the S&P 500's 10.2% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and operates in the Medical-Products industry which ranks in the bottom 35% of Zacks industries.
Rockwell Medical reported Q2 2025 earnings with a 37.8% revenue decline due to losing its largest customer, but signed four new multi-year supply agreements and maintained tight cost controls.
DaVita's stock has gained 47.3% year-to-date, outperforming the industry and the S&P 500. The rally is attributed to the company's strong dialysis and lab services, solid Q2 2024 performance, and expansion through acquisitions.
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.